venous thromboembolism (VTE) research hub
4 indexed studies · 3 currently recruiting
- ongoing, recruitingPhase II and Phase III (Integrated)
A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
This study looks at a new drug, abelacimab, compared to a standard drug, apixaban, for treating blood clots in veins (VTE) in people with cancer. The main goal is to see which drug is better at preventing new clots and causing less bleeding over six months.
Latvia · Ireland · Italy - recruitingPHASE1
A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in Healthy Adults, Adults With FV Leiden or Prothrombin G20210A Mutation, and Adults With a History of Provoked Venous Thromboembolism
This study is testing a new medicine, CITY-FXI, for safety in healthy adults and those with specific blood clotting conditions. It's the first time this medicine is being given to people to see how their bodies react.
United Kingdom - recruitingNA
Delivery and Implementation of a Randomised Crossover Trial on Thrombosis
The DIRECT study aims to find the best way to prevent dangerous blood clots after a hip fracture. It compares two treatments: daily aspirin tablets and low molecular weight heparin (LMWH) injections. This large UK study will help doctors decide if aspirin is a safe and easier option for patients, potentially saving the NHS money.
United Kingdom - recruitingPHASE4
Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk
This study looks at whether a blood-thinning medicine called LMWH can prevent dangerous blood clots in new mothers who have a medium risk of getting them after childbirth. It compares taking the medicine for 6 weeks to not taking it.
France